Differential regulation of gonadotropin hormone production in the pituitary is critical for fertility. Activin and progesterone signaling in gonadotrope cells is important for Fshb gene expression. Previously, we reported that synergy between activin and progestins required the binding of SMAD proteins and the progesterone receptor (PR) to the murine Fshb promoter. In this study, we demonstrate that the FOXL2 transcription factor is also necessary for the full synergistic response between activin and progestins. We show that this synergy occurs in a species-specific manner and that multiple elements in the Fshb promoter that bind forkhead box L2 (FOXL2), SMA/mothers against decapentaplegic homologs (SMAD), and PR are required. Furthermore, we demonstrate that FOXL2 can physically interact with PR and SMAD3. Thus, it is likely that protein-protein interactions among FOXL2, SMAD, and PR recruited to the Fshb promoter play a key role in facilitating Fshb transcription before the secondary FSH surge in rodents. 
F
SH and LH are essential for mammalian fertility because they are required for ovarian folliculogenesis, gametogenesis and steroidogenesis (1) . Gonadotropins are heterodimeric glycoproteins composed of a common ␣-glycoprotein subunit and unique ␤-subunits that confer biological specificity. Transcription of the ␤-subunits is the rate-limiting step for production of the mature hormones (2, 3) and is differentially regulated during the estrous cycle. The LH surge is proceeded by an increase in Lhb and Fshb transcription in the afternoon of proestrus (4 -6) , while an independent secondary FSH surge occurs, after an increase in Fshb transcription during estrus, to promote follicular recruitment for the following cycle (3, 7, 8) .
Multiple mechanisms have been proposed for the distinct regulation of Fshb vs. Lhb transcription (recently reviewed in Refs. 9 and 10). Pulsatile secretion of GnRH contributes to differential regulation of FSH and LH (2, 11, 12) . In addition, an increase in activin levels during estrus, due to lower follistatin and/or inhibin, is thought to selectively favor Fshb synthesis (13, 14) . Furthermore, steroid hormones such as progesterone have been shown to induce Fshb while inhibiting Lhb expression (15, 16) .
Activin strongly induces Fshb expression in gonadotrope cells (17) . Activin binding to the type II receptor leads to heterodimerization and phosphorylation of the type I receptor (18) . Subsequently, the type I receptor phosphorylates SMA/mothers against decapentaplegic homologs (SMAD) 2 and SMAD3, which bind to SMAD4 and translocate into the nucleus to mediate transcription of specific target genes (18 -20) . The proximal murine Fshb promoter contains multiple activin responsive elements (reviewed in Refs. 21 and 22) . The Ϫ267 SMADbinding element (SBE) in the murine Fshb promoter is a consensus SBE comprised of a palindrome sequence GTCTAGAC (23) (24) (25) . Two other elements at Ϫ153 and Ϫ120 are critical for activin induction in all species examined (26) . The TALE homeodomain proteins, PBX1 and PREP1 bind the Ϫ120 site, which allows tethering of SMAD to the promoter (26, 27) , whereas the forkhead box L2 (FOXL2) transcription factor was recently shown to bind the Ϫ153 element (28, 29) . Indeed, Fshb mRNA levels are reduced in both FOXL2-and SMAD3-null mice, indicating these transcription factors are required for normal Fshb expression (30, 31) .
Differential regulation of gonadotropin gene expression may be due to interactions among the hormone signaling pathways that regulate their synthesis. Cross talk between activin and progesterone may be important for the secondary FSH surge because FSH levels were reported to increase upon activin and progesterone cotreatment in primary rat pituitary cell cultures and a progesterone antagonist suppressed activin induction of Fshb gene expression in vivo in rats (32, 33) . Another study revealed that progesterone stimulation of FSH secretion was prevented by follistatin treatment in rats (34) . More recently, we showed synergistic induction of the Fshb promoter with activin and progestin cotreatment of murine primary pituitary cells as well as immortalized gonadotrope-derived L␤T2 cells (35) . We also demonstrated that SMAD can physically interact with progesterone receptor (PR) and that both transcription factors were required to bind to the Fshb promoter for the synergy (35) .
In this study, we further investigated mechanisms of Fshb transcriptional regulation mediated by cross talk between activin and progestin signaling pathways using L␤T2 cells. During the course of our investigations, we and others discovered that FOXL2 plays a role in activin induction of the Fshb promoter (28, 29) . Therefore, we shifted our focus to understanding the potential role of FOXL2 in mediating activin and progestin synergy on the Fshb promoter. We show that the FOXL2 transcription factor is involved in activin and progestin synergy on the murine Fshb promoter and that the synergy occurs in a species-specific manner. We demonstrate that a Ϫ355 SMAD half-site and an adjacent Ϫ350 FOXL2 site are necessary for the full synergistic response along with a previously characterized Ϫ381 hormone response element (HRE) and Ϫ267 SBE. We also show that additional activin and progesterone-responsive elements are necessary for the maximal response. Furthermore, we demonstrate that FOXL2 physically interacts with PR, suggesting that interactions among FOXL2, SMAD, and PR may play a role in elevated Fshb synthesis before the secondary FSH surge in rodents.
Materials and Methods

Hormones
Promegestone (R5020) was purchased from NEN Life Science Products Life Sciences (Boston, MA), activin from Calbiochem (La Jolla, CA), and GnRH from Sigma-Aldrich (St. Louis, MO).
Plasmid constructs
The construction of the Ϫ1000 murine Fshb and Ϫ985 ovine FSHB luciferase (luc) reporter plasmids were described previously (16, 36) . The Ϫ1028/ϩ7 human FSHB-luc reporter plasmid was provided by Daniel Bernard, murine PRB by Dean Edwards, and murine FOXL2 and FOXL2 ⌬133-375 by Louise Bilezikjian (37) .
Mutagenesis
The QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used to generate deletions or mutations in plasmids containing the murine and human FSHB promoters. Insertion of the Ϫ381 HRE and/or the Ϫ267 SBE into the human FSHB promoter was performed with the following primers: 5Ј-TTTGTTTCTTC-CTTCACAGTGTTCAATATGCTCTTGGAGCAATTT-3Ј and 5Ј-AAAGATACAAAAGAAAAGTCTAGACTCTGGAGTCAC AATTAATT-3Ј (the mutated bases are indicated in bold). The sequences of the promoters were confirmed by dideoxyribonucleotide sequencing. The Ϫ381, Ϫ273, Ϫ230, Ϫ197, and Ϫ139 HRE mutations in the murine Fshb-luc reporter plasmid were described previously (16) as well as the Ϫ267, Ϫ153, Ϫ120, and 3xSBE mutations (35) . The Ϫ355 SMAD, Ϫ350 FOXL2, Ϫ339 SF1, Ϫ355 SMAD/Ϫ350 FOXL2, Ϫ208 (5Ј T), Ϫ153 (3Ј T), and Ϫ106 mutations were also previously described (29, 38) .
Cell culture and transient transfections
Cell culture and transient transfection experiments were performed using the L␤T2 cell line (39, 40) . The cells were maintained in 10-cm plates in DMEM from Mediatech Inc. (Herndon, VA) with 10% fetal bovine serum (Omega Scientific, Inc., Tarzana, CA) and penicillin/streptomycin antibiotics (Life Technologies, Inc./Invitrogen, Grand Island, NY) at 37 C and 5% CO 2 . Trypsin-EDTA (1ϫ) (Sigma-Aldrich) was used for cell dissociation. Cells were split at 3 ϫ 10 5 cells per well into 12-well plates and transfected 18 h later, using Fugene 6 reagent (Roche Molecular Biochemicals, Indianapolis, IN) following the manufacturer's instructions. For all experiments, the cells were transfected with 400 ng of the indicated reporter plasmid, 10 ng of mouse PRB expression vector, and 200 ng of a ␤-galactosidase reporter plasmid driven by the herpes virus thymidine kinase promoter to control for transfection efficiency. Cells were switched to serum-free DMEM containing 0.1% BSA, 5 mg/liter transferrin, and 50 mM sodium selenite 6 h after transfection. The cells were treated with various hormones after overnight starvation in serum-free media. Vehicle control for R5020 was 0.1% ethanol; for activin and GnRH, it was 0.1% BSA. The cells were treated with 10 ng/ml activin (unless stated otherwise), 10 Ϫ9 M R5020 for 24 h or 10
Ϫ8 M GnRH for 6 h.
Luciferase and ␤-galactosidase assays
After hormone treatment, cells were washed with 1ϫ PBS and lysed with 0.1 M K-phosphate buffer (pH 7.8) containing 0.2% Triton X-100. Lysed cells were assayed for luciferase activity using a buffer containing 100 mM Tris-HCl (pH 7.8), 15 mM MgSO 4 , 10 mM ATP, and 65 M luciferin. ␤-Galactosidase activity was assayed using the Tropix Galacto-light assay (Applied Biosystems, Foster City, CA), according to the manufacturer's protocol. Both assays were measured using a Veritas Microplate Luminometer (Promega, Madison, WI).
Glutathione S-transferase (GST) interaction assay
GST-FOXL2 was creating by ligating Flag-tagged murine FOXL2 (37) into the BamHI and EcoRI sites of the pGEX-5X-1 expression vector. GST-SMAD3 was provided by Rik Derynck. 35 S-labeled proteins were produced using the TnT Coupled Reticulolysate System (Promega). Bacteria transformed with GST plasmids were grown to OD of 0.6 and induced with isopropyl ␤-D-1-thiogalactopyranoside overnight at 30 C (41). Bacterial pellets were sonicated in 0.1% Triton X-100, 5 mM EDTA in 1ϫ PBS and centrifuged, and the supernatant was bound to glutathione Sepharose 4B resin (Amersham Pharmacia Biotech, Piscataway, NJ). Beads were washed 4ϫ in PBS and in Hepes/NaCl/ dithiothreitol (HND) buffer [10 mg/ml BSA, 20 mM HEPES (pH 7.8), 50 mM NaCl, 5 mM dithiothreitol, and 0.1% Nonidet P-40]. For the interaction assay, 40 l of 35 S-labeled in vitro transcribed-translated PR or 5 l of green fluorescent protein (GFP) was added to the beads with 400 l HND buffer. Beads were incubated overnight at 4 C and washed twice with HND buffer and twice with 0.1% Nonidet P-40 in PBS. Thirty microliters of 2ϫ Laemmli load buffer were added, and the samples were boiled and electrophoresed on a 10% SDS-polyacrylamide gel. One tenth of the 35 S-labeled in vitro transcribed-translated product was loaded onto the gel as input.
Statistical analysis
Transient transfection experiments were repeated independently at least three times. Data were normalized for transfection efficiency with luciferase activity relative to ␤-galactosidase. Data were also normalized to the pGL3 plasmid (to control for hormone effects on the vector DNA). In the figures, the error bars represent the SEM. Data were analyzed by one-way ANOVA, followed by post hoc comparisons with the Tukey-Kramer honestly significant difference test or two-way ANOVA to determine synergy (as described in Ref. 42 ) using the statistical package JMP version 9.0 (SAS, Cary, NC). In all analyses, the result was considered significant if P Յ 0.05.
Results
Low levels of exogenous PR are sufficient for progestin responsiveness and synergy between activin and progestins on the Fshb promoter
One concern from our previous studies was the high levels of exogenous PR transfected into L␤T2 cells to measure progestin responsiveness (16, 35) . In the current study, we performed a titration to determine the minimal effective level of PR for progestin induction of the murine Fshb promoter (Fig. 1A) . Because 10 ng PR resulted in a robust induction, we used this amount of receptor for all of the subsequent experiments. Ten nanograms of PR resulted in an 11-fold response to R5020 (a synthetic progestin) on the Fshb promoter, whereas the synergistic response to activin and progestin was 47-fold (Fig. 1B ).
GnRH and progestin signaling pathways do not synergize on the Fshb promoter
As shown previously (23, 35, 43) , activin with progestins or activin with GnRH synergistically enhanced transcription of a Fshb-luc reporter (Fig. 1B) . Because activin, GnRH, and progesterone are all present during the estrous cycle to regulate Fshb gene expression, we investigated whether GnRH and progestin signaling pathways interact to mediate Fshb gene expression. As shown in Fig. 1B , GnRH induced the Fshb promoter 2.6-fold and R5020 11-fold. However, GnRH and R5020 cotreatment up-regulated Fshb gene expression 12-fold, indicating that they do not interact to regulate the Fshb promoter.
Synergy between activin and progestins is not conserved on the ovine and human FSHB promoters
Activin has been shown to regulate ovine FSHB gene expression by SMAD and TGF-␤-activated kinase-1-de- Ϫ9 M R5020 (P), or 10 nM GnRH (G), individually or with the indicated combinations. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the vehicle-treated control using one-way ANOVA followed by Tukey's post hoc test; #, significant interaction as defined by two-way ANOVA (42) . pendent signaling pathways (26, 44, 45) . It is less clear whether progesterone modulates transcription of ovine FSHB in gonadotropes. FSHB mRNA levels decreased after progestin treatment in ovine primary pituitary cells (46) . On the other hand, a reporter gene containing the proximal ovine FSHB promoter was induced by progesterone in ovine primary pituitary cells (47) . Data regarding transcriptional regulation of the human FSHB gene by activin and progestins are limited. The human FSHB promoter has been reported to be relatively insensitive to activin treatment (48, 49) . A polymorphism in the human FSHB promoter was mapped to a conserved region containing a putative HRE, suggesting that progestin regulation of FSHB synthesis may be conserved among mammals (50) .
To determine whether the ovine and human promoters respond to progestins alone or synergistically with activin and progestins, Ϫ1000 murine, Ϫ985 ovine, or Ϫ1028/ϩ7 human FSHB-luc reporter constructs were transiently transfected into L␤T2 cells along with PR ( Fig. 2A) . In contrast to the murine promoter, which was induced 15-fold by progestin treatment and 82-fold by activin and progestins, the ovine and the human FSHB promoters did not exhibit significant progestin responsiveness alone or in the presence of 50 ng/ml activin.
Addition of the ؊381 HRE and/or the ؊267 SBE to the human FSHB promoter is not sufficient for activin and progestin synergy
The Ϫ267 SBE is present in rodent Fshb promoters but is not conserved in other mammalian species. Addition of the Ϫ267 SBE to the human FSHB promoter increased activin responsiveness (48) . The Ϫ381 HRE is necessary for the synergistic induction of murine Fshb gene expression by activin and progestins, because mutating it reduced the synergy by 73% (35) . We, therefore, investigated whether addition of the murine Ϫ381 HRE, Ϫ267 SBE, or both to the human FSHB promoter would be sufficient to observe synergy between activin and progestins. With the addition of the Ϫ267 SBE site, the human FSHB promoter responded to activin 3-fold more than the wildtype human promoter, as previously demonstrated (48) . On the other hand, addition of the Ϫ381 HRE did not result in progestin responsiveness or synergy between activin and R5020, indicating that the Ϫ381 HRE is not sufficient (Fig. 2B) . Furthermore, although addition of the Ϫ267 SBE to the human promoter resulted in substantial activin responsiveness, it was unable to facilitate activin and progestin synergy.
The ؊273, ؊230, ؊197, and ؊139 HRE are necessary for activin and progestin synergy
In addition to the Ϫ381 HRE, several other HREs on the murine Fshb promoter are necessary for the full progestin response (16) (Fig. 3A) . Because the Ϫ381 HRE is not sufficient for the synergy between activin and progestins, mutations in these additional HRE sites were tested for responsiveness to activin, progestins, and cotreatment. The Ϫ273 and Ϫ139 HRE mutations resulted in a significant decrease in the activin response, perhaps due to proximity of these sites to the Ϫ267 and Ϫ153 activin responsive elements, respectively (Fig. 3B) . The Ϫ197 HRE mutation increased the activin response by approximately 50%, probably due to enhancement of the adjacent Ϫ208 activin responsive element as an unintended consequence of the mutation. Indeed, an individual base-pair change at Ϫ193 instead of the double mutation at Ϫ196 and Ϫ193 did not exhibit an increased activin response (see Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). All HRE mutants showed a significant decrease in progestin responsiveness and synergistic induction by activin and R5020 cotreatment (Fig. 3B) . The Ϫ381 HRE mutation A B
FIG. 2.
Activin and progestin synergy is not conserved on the ovine and human FSHB promoters and addition of the Ϫ381 HRE and/or Ϫ267 SBE to the human FSHB promoter is not sufficient for synergy. A, The Ϫ1000 murine (m), Ϫ985 ovine (o), or Ϫ1028/ϩ7 human (h) FSHB-luc reporter constructs were transiently transfected into L␤T2 cells, as indicated. B, Wild-type (WT) Ϫ1028/ϩ7 hFSHB-luc or mutants containing the Ϫ381 HRE, Ϫ267 SBE, or both were transiently transfected into L␤T2 cells, as indicated. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 50 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the vehicle-treated control using one-way ANOVA followed by Tukey's post hoc test; #, significant interaction as defined by two-way ANOVA.
resulted in a complete lack of responsiveness to R5020 alone or in combination with activin.
Disruption of individual activin-responsive elements prevents cross talk between activin and progestins
The expression of a luciferase reporter containing three mutated activin-responsive elements in the murine Ϫ1000 Fshb proximal promoter (3xSBE) was previously studied for its responsiveness to activin and progestins (35) . Here, we measured responsiveness to activin, R5020, and cotreatment of individual mutations in these elements. Mutations in the Ϫ267, Ϫ153, and Ϫ120 elements showed a significant decrease in activin responsiveness compared with the wild-type promoter (Fig. 3C) . None of the mutated promoters showed any significant difference in their progestin response. The synergistic induction of the mutated promoters due to activin and R5020 cotreatment was significantly reduced (Fig. 3C) . The 3xSBE mutation led to a complete lack of response to activin alone or cotreatment with activin and progestins, as previously reported (35) .
The region between the ؊381 HRE and the ؊267 SBE contains a FOXL2 site and SMAD half-site necessary for synergy between activin and progestins Because it appeared, from our studies, that additional elements might be involved in the synergy between activin and progestins (Fig. 2) and that the Ϫ381 HRE, Ϫ273 HRE, and Ϫ267 SBE are important elements for this synergy (Fig. 3) , we undertook a systematic analysis of the region between these elements. Internal deletions of 10 bp from Ϫ370 to Ϫ271 in the murine Ϫ1000 Fshb promoter were created because the helical periodicity of DNA is approximately 10 bp per turn, and the orientation of the promoter DNA would not be altered. The responsiveness of the 10-bp deletions to activin, progestin, or cotreatment was measured. The Ϫ370/Ϫ361 deletion overlapped the last 4 bp of the 3Ј end of the Ϫ381 HRE and thus led to a significant reduction of R5020 responsiveness and synergy compared with the wild-type promoter (Fig. 4) . Deletions at Ϫ360/Ϫ351, Ϫ350/Ϫ341, and Ϫ320/Ϫ311 also resulted in significant reductions in the induction of Fshb gene expression by R5020 and cotreatment (Fig. 4) . The Ϫ320/Ϫ311 region was recently identified as playing a role in activin induction of the Fshb promoter (29) , but it remains to be determined what transcription factors bind to this region.
Closer examination of the 10-bp internal deletions from Ϫ360 to Ϫ341 found that a putative SMAD half-site at Ϫ355 bp and a newly characterized FOXL2 site at . B and C, The wild-type (WT) Ϫ1000 mFshb-luc reporter and mutations in specific response elements were transiently transfected into L␤T2 cells, as indicated. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 10 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the wild-type Fshb promoter using one-way ANOVA followed by Tukey's post hoc test.
FIG. 4.
The 10-bp internal deletions between the Ϫ381 HRE and the Ϫ267 SBE reveal several regions involved in activin and progestin synergy on the murine Fshb promoter. The wild-type (WT) Ϫ1000 mFshb-luc reporter or mutants with the indicated 10-bp deletions were transiently transfected into L␤T2 cells. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 10 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the vehicle-treated control using one-way ANOVA followed by Tukey's post hoc test; #, significant interaction as defined by two-way ANOVA.
Ϫ350 bp described by Corpuz et al. (29) (Fig. 5A) had been deleted. The expression of specific mutations in each of the above-mentioned sites and a double mutant was measured to understand the effects of these sites on hormonal induction of the Fshb promoter. As expected from the deletion studies, mutation of a putative SF1 site did not significantly alter Fshb induction by activin, R5020, or cotreatment (Fig. 5B) , indicating that this element does not play a significant role. The Ϫ355 SMAD half-site and the Ϫ350 FOXL2 site mutations did not significantly alter activin induction of the Fshb promoter. On the other hand, mutation of the Ϫ355 SMAD half-site reduced the progestin response by 53% and the synergistic induction by 49% of the wild-type promoter induction. Similarly, the Ϫ350 FOXL2 mutation reduced the progestin response by 58% and synergistic induction by 70% of the wild-type promoter. Interestingly, the SMAD half-site/ FOXL2 double mutation decreased the progestin response and the synergy by approximately 80 -90% of the wildtype promoter without significantly reducing activin induction.
Because the Ϫ355 putative SMAD half-site and the Ϫ350 FOXL2 site are located between the Ϫ381 HRE and Ϫ267 SBE, we hypothesized that these sites may help to stabilize a ternary complex formed by PR, SMAD, and FOXL2. If this is the case, bringing the Ϫ381 HRE and Ϫ267 SBE closer together on the promoter may remove the necessity for the SMAD and FOXL2 sites. Deletions of 21 or 85 bp were created in the murine Fshb promoter from Ϫ359/Ϫ338 and Ϫ359/Ϫ274, respectively. Similarly to Fig. 5B , the Ϫ359/Ϫ338 deletion encompassing the SMAD half-site and FOXL2 site significantly reduced Fshb gene expression (Fig. 5C) . Notably, because the Ϫ381 HRE and the Ϫ267 SBE were brought closer together with the 85-bp deletion, the progestin response and the synergy were partially rescued. For the 21-and 85-bp deletions, the progestin response was reduced by 66 and 30%, whereas the synergy was reduced by 81 and 44% of the wild-type promoter, respectively (Fig. 5C ).
The ؊208, ؊153, and ؊106 FOXL2 sites are necessary for maximal synergistic response
In addition to the Ϫ350 FOXL2 site, several other FOXL2 sites have been recently characterized that play a role in activin induction of the murine Fshb promoter (28, 29, 51) . We used specific mutations in the Ϫ208, Ϫ153, and Ϫ106 elements to determine whether they are also necessary for progestin responsiveness and the synergy between activin and progestins. In the Ϫ208 (5Ј T) mutation, two thymines at Ϫ204 and Ϫ203 were changed to cytosines, whereas in the Ϫ153 (3Ј T) mutation, three thymines at Ϫ142/Ϫ140 were altered to guanines (Fig. 6A ) (29) . The Ϫ208 (5Ј T) mutation reduced the response to activin, progestins, and cotreatment by 69, 25, and 54% of the wild-type response, respectively, whereas the Ϫ153 (3Ј T) mutation reduced the response to activin, progestins, and cotreatment by 61, 24, and 66% (Fig. 6B) . The Ϫ106 mutation (38) reduced the response to activin and cotreatment by 60 and 25% of the wild-type response, whereas the response to progestins was increased by 23%.
Overexpression of a dominant-negative (DN) FOXL2 reduces synergy between activin and progestins on the Fshb promoter
Because FOXL2 binding sites are necessary for activin and progestin synergy, we asked whether the FOXL2 transcription factor is required for the synergy to occur. Transient transfection of L␤T2 cells with an expression plasmid containing murine FOXL2 resulted in only a slight putative SMAD half-site, Ϫ350 FOXL2 site, and Ϫ339 putative SF1 site on the murine Fshb promoter. B, The wild-type (WT) Ϫ1000 mFshb-luc reporter or mutations in specific sites were transiently transfected into L␤T2 cells, as indicated. C, The WT Ϫ1000 mFshb-luc reporter construct or deletions in the region between the Ϫ381 HRE and the Ϫ267 SBE were transiently transfected into L␤T2 cells, as indicated. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 10 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the wild-type Fshb promoter using one-way ANOVA followed by Tukey's post hoc test.
increase in Fshb gene expression compared with the empty vector, likely due to the fact that the cells already contain high levels of FOXL2 protein. L␤T2 cells were also transfected with an expression plasmid containing FOXL2 ⌬133-375, which lacks part of the DNA-binding forkhead domain and the carboxyl-terminal alanine-rich region (Fig. 7A) . Several mutations in patients with blepharophimosis-ptosis-epicanthus inversus syndrome produce truncated proteins lacking part of the forkhead-binding domain and/or a polyalanine tract (52, 53) . Truncated FOXL2 proteins have been shown to exert DN effects on wild-type FOXL2 (54) . Overexpression of the DN FOXL2 ⌬133-375 resulted in 40% reduction in the synergy between activin and progestins (Fig. 7B ).
FOXL2 interacts with PR and SMAD3
Because FOXL2 is necessary for the maximal synergistic response between activin and progestins on the murine Fshb promoter, we investigated whether FOXL2 can physically interact with PR. FOXL2 has been reported to interact with SMAD3 (37), and we have shown that SMAD2, -3, and -4 can interact with PR (35) . We tested whether FOXL2 interacts with PR by incubating a GST-FOXL2 fusion protein with in vitro-transcribed and -translated PR in pull-down experiments (Fig. 7C) . FOXL2 bound to both the full-length PRB and PRA isoforms. As a positive control, we also showed that FOXL2 interacts with SMAD3, as previously reported (37) . In contrast, there was minimal interaction between the GST-FOXL2 fusion protein and the negative control (GFP) or with GST alone incubated with PR (Fig. 7C) .
Discussion
Interactions among multiple hormone signaling pathways are likely responsible for the differential regulation of Fshb synthesis before the secondary FSH surge. In investigating combinatorial interactions among activin, progestins, and GnRH, we first confirmed that there are synergistic interactions between activin and progestins or activin and GnRH on the murine Fshb promoter, as previously reported (23, 35, 43) . In contrast, our studies demonstrate that there is no significant interaction between GnRH and progestins on the murine Fshb promoter in L␤T2 cells. This is particularly interesting because cross talk with PR A B   FIG. 6 . The Ϫ208, Ϫ153, and Ϫ106 FOXL2 sites are necessary for the full synergistic response between activin and progestins on the murine Fshb promoter. A, Schematic of the FOXL2 sites on the mFshb promoter with the mutated bases underlined (29, 38) . B, The Ϫ1000 mFshb-luc reporter or mutants were transiently transfected into L␤T2 cells, as indicated. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 10 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the wild-type Fshb promoter using one-way ANOVA followed by Tukey's post hoc test. FOXL2 and DN FOXL2 ⌬133-375 . B, The Ϫ1000 mFshb-luc reporter was transiently transfected into L␤T2 cells along with empty vector (EV), wild-type or DN FOXL2, as indicated. After overnight starvation in serum-free media, cells were treated for 24 h with vehicle (veh), 10 ng/ml activin, 10 Ϫ9 M R5020, or both. The results represent the mean Ϯ SEM of at least three experiments. *, Significant difference from the wild-type Fshb promoter using one-way ANOVA followed by Tukey's post hoc test. C, GST interaction assays were performed using bacterially expressed GST-fusion proteins (indicated above each lane) and 35 S-labeled in vitro-transcribed and -translated PRB, PRA, and GFP (indicated on the left). GFP was used as a negative control. The GSTfusion proteins included GST alone, GST-FOXL2, and GST-SMAD3. One tenth of the protein used in the interaction assay was loaded in the lane marked input. The experiment was repeated several times with the same results, and a representative experiment is shown.
has been implicated as critical for GnRH self-priming in pituitary gonadotropes (55, 56) , and progestins inhibit GnRH induction of Lhb gene expression (57) , suggesting that interactions between GnRH and progesterone signaling pathways may be important for LH synthesis and secretion but not for Fshb transcriptional regulation.
Several of the HREs previously characterized in the murine Fshb promoter have a degree of conservation across multiple species, suggesting that steroid hormones such as progesterone may regulate other mammalian FSHB promoters (16) . However, we demonstrated that neither the ovine nor human promoter exhibited a progestin response or synergistic induction of the promoter upon cotreatment with activin and progestins. This result suggests that progesterone does not directly regulate ovine or human FSHB transcription in gonadotrope cells due to the lack of species-specific regulatory elements present on the rodent promoter. Because our data differ from what was observed in ovine primary pituitary cells with an ovine FSHB-luc reporter (47), they suggest that the progesterone induction observed in ovine pituitary cells was due to paracrine influences from other cells in the primary cultures. On the other hand, our results agree with experiments in sheep and ovine pituitary cells showing that progestins do not up-regulate FSHB mRNA (46, 58) .
To test whether elements in the murine promoter, not conserved in the ovine and human promoters, are sufficient to induce a progestin response and synergy with activin, we inserted the murine Ϫ381 HRE, Ϫ267 SBE, or both into the human FSHB promoter. Addition of the Ϫ267 SBE resulted in a substantial activin response, as previously described (48) . In contrast, addition of the Ϫ381 HRE to the human FSHB promoter was not sufficient for a progestin response alone or in combination with activin, suggesting that additional regulatory elements are required.
Because the extent of steroid hormone response conveyed by a single HRE is often weak, multiple HRE are often found in the promoters of steroid-responsive genes (59) . We confirmed that the Ϫ381 HRE is required for the progestin response and for synergistic induction of the promoter by activin and progestin cotreatment, in agreement with our previous studies (16, 35) . We also showed that additional HRE previously characterized on the murine Fshb promoter at Ϫ273, Ϫ230, Ϫ197, and Ϫ139 as playing a role in the progestin response (16) are also necessary for maximal synergistic induction of the promoter by activin and progestins. It is noteworthy that mutation of the elements at Ϫ273, Ϫ197, and Ϫ139 also affected activin responsiveness, possibly due to the proximity or overlap of these sites with the Ϫ267 SBE, Ϫ208, and Ϫ153 FOXL2 sites, respectively. These results also indicate that there may be strong coregulation between elements that bind PR and FOXL2/SMAD.
Our previous studies showed that SMAD binding to the Fshb promoter was necessary for the synergistic interaction between activin and progestins (57) . As previously reported, mutation of three activin-responsive elements (3xSBE) led to a lack of activin responsiveness and disappearance of the synergistic induction of the promoter. Individual disruption of the Ϫ267 SBE substantially reduced cross talk between activin and progestins and did not allow for maximal synergistic induction of the promoter. However, mutation of the Ϫ267 SBE did not completely abolish activin induction or synergy on the Fshb promoter, indicating that this hormonal regulation requires the binding of additional factors to multiple activin-responsive elements in the Fshb promoter. PBX1/PREP1 were reported to bind a CTGTCTATCCAA element encompassing a putative SMAD half-site (underlined) at Ϫ120 in the murine Fshb promoter and recruit SMAD3/4 to the promoter (26) . Not surprisingly, mutation of the Ϫ120 element not only blocked activin induction, as previously described, but also greatly reduced the synergy between activin and progestins. These data confirm that activin signaling through SMAD proteins is critical for synergy between activin and progestins on the Fshb promoter.
In addition to transcription factors such as SMAD and PBX1/PREP1, recent studies have characterized the binding of the FOXL2 transcription factor at several elements in the murine Fshb promoter (28, 29) . In the current experiments, mutation of the Ϫ350 FOXL2 site and a nearby Ϫ355 putative SMAD half-site had little effect on activin responsiveness, in contrast to our previous study, which showed a significant reduction with a mutation of the Ϫ350 FOXL2 site (29) . It remains to be determined whether the Ϫ355 element is a bona fide SBE because SMAD4 did not supershift protein complexes bound to an oligo encompassing this site (29) . On the other hand, deletion or disruption of these two sites greatly reduced the response to progestins, alone or in combination with activin (Figs. 4 and 5, B and C) . Indeed, a double FOXL2/ SMAD mutation almost completely abolished progestin responsiveness. These results indicate that the FOXL2 site and nearby SMAD half-site are necessary for progestin responsiveness and the synergy between activin and progestins on the murine Fshb promoter. They also suggest that these elements play a role in supporting progestin action at the nearby Ϫ381 HRE via protein-protein interactions among FOXL2, SMAD, and PR. The fact that the Ϫ359/Ϫ274 deletion (which moved the Ϫ273 HRE and Ϫ267 SBE much closer to the Ϫ381 HRE) partially restored progestin responsiveness and synergy between activin and progestins also suggests that multiple elements are necessary to stabilize interactions among SMAD, FOXL2, and PR on the Fshb promoter.
We also determined whether additional FOXL2 binding elements that play a role in activin responsiveness on the murine Fshb promoter also play a role in progestin responsiveness alone or in combination with activin. Interestingly, these FOXL2 elements are in close proximity to other elements important for the synergy. Because the Ϫ208 FOXL2 element overlaps the Ϫ197 HRE by 2 bp, we mutated the 5Ј T to try to separate the effect of FOXL2 vs. PR. The 5Ј T mutation resulted in a decrease in progestin responsiveness and the synergy (Fig. 6B) , in addition to the previously reported effect on activin induction (29) . The Ϫ153 FOXL2 element (originally identified as a putative SMAD half-site at Ϫ149) (26) overlaps the Ϫ139 HRE by 2 bp. Mutation of residues in the SMAD half-site reduced activin response and, thus, the synergy (Fig. 3C) , whereas the 3Ј T mutation also decreased progestin induction of Fshb (Fig. 6B) . Mutation of the Ϫ106 FOXL2 site increased progestin response, but the synergy was still reduced, presumably due to the role of the Ϫ106 element in activin induction (Fig. 6B) . Similarly to the Ϫ350 FOXL2 site, these results suggest that the Ϫ208, Ϫ153, and Ϫ106 FOXL2 elements are necessary for a maximal progestin response and synergy between activin and progestins. This idea is supported by the fact that cotransfection with the DN FOXL2 ⌬133-375 reduced the synergistic induction of Fshb gene expression by activin and progestins.
Because FOXL2 is necessary for the full synergistic response between activin and progestins, we tested whether there was a direct interaction between FOXL2 and PR. Using a GST interaction assay, we showed that FOXL2 can physically interact with PR as well as with SMAD3. Our data expand the set of proteins that can directly partner with FOXL2. Moreover, these results also suggest that FOXL2 may interact with PR directly and/or indirectly via SMAD3 and that a tripartite complex of FOXL2, SMAD, and PR may be important for the synergy between activin and progestins on the murine Fshb promoter.
In summary, our experimental results provide evidence that the FOXL2 transcription factor is involved in the cooperative interaction between activin and progesterone signaling pathways in pituitary gonadotrope cells. We demonstrate that the murine Fshb promoter contains a cluster of species-specific elements critical for activin and progestin synergy that may play a crucial role in the rapid elevation in Fshb mRNA before the secondary FSH surge in rodents. These elements are conserved on the rat promoter and likely function in a similar manner. In contrast, the ovine and human FSHB promoters are not induced by progestins alone or in combination with activin, suggesting that other mechanisms regulate FSHB gene expression in these species. Our data also indicate that the cooperation between activin and progesterone signaling pathways requires the binding of FOXL2, SMAD, and PR to their respective elements on the murine Fshb promoter and suggest that physical interactions among these transcription factors may be important for the synergy. Future experiments characterizing these interactions will shed light on how synergy between activin and progesterone signaling pathways regulates reproductive fitness. Cooperation among transcription factors such as FOXL2, SMAD, and PR may also prove to be important for the regulation of gene expression in other reproductive tissues such as the ovary (60) .
